Financials
Financial year 2025
MARBLE PHARMA CONSULT from Lasne, company number BE0889606695, closed financial year 2025 with a result of € 197,414 after tax. For that financial year MARBLE PHARMA CONSULT recorded a gross margin of € 449,455 and equity of € 853,832. Compared with financial year 2024, the result moved from € 97,564 to € 197,414. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 10, 2026.
€ 853,832
▲ 30% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 197,414
▲ 102% vs 2024
Profit after tax over the fiscal year.
€ 259,082
▲ 146% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 841,432.
People and assets in 2025
€ 161,330
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 4,022
▼ 35% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 87,224
▼ 17% vs 2024
€ 19,800 is repaid this year. At this pace the long-term loan is gone in ≈ 4 years.
€ 39,570
▲ 42% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 17,953
▲ € 17,013 vs 2024
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 158,060 | € 273,104 | € 166,326 | € 449,455 | ▲ 170% |
| Profit after taxes | € 95,122 | € 171,386 | € 97,564 | € 197,414 | ▲ 102% |
| Equity | € 577,879 | € 649,265 | € 656,418 | € 853,832 | ▲ 30% |
| Total debts | € 205,475 | € 155,557 | € 134,020 | € 146,796 | ▲ 10% |
| Cash | € 386,520 | € 110,554 | € 105,470 | € 259,082 | ▲ 146% |
| Land & buildings | € 235,439 | € 227,935 | € 220,431 | € 212,926 | ▼ 3% |
| Retained profit | € 565,479 | € 636,865 | € 644,018 | € 841,432 | ▲ 31% |
| Dividend | € 0 | € 100,000 | € 90,411 | € 0 | ▼ 100% |
| Bank debt | € 144,083 | € 125,541 | € 105,303 | € 87,224 | ▼ 17% |
| Balance sheet total | € 783,354 | € 804,822 | € 790,438 | € 1,000,628 | ▲ 27% |
Key figures of MARBLE PHARMA CONSULT, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to MARBLE PHARMA CONSULT?
What happened at MARBLE PHARMA CONSULT in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: profit of € 197,414 (▲ 102% vs 2024). Source: NBB ↗
- New establishment in Lasne. KBO
- Start of the company according to the CBE. KBO
In short
From € 95,122 profit in 2022 to € 197,414 profit in 2025.
Paid € 215,936 in corporate taxes since 2022.
Best year ever: 2025, with € 197,414 profit.
Paid out € 190,411 in dividends to the owners in total.
A new publication or filing at MARBLE PHARMA CONSULT? We notify you, reason included.
Follow MARBLE PHARMA CONSULTDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind MARBLE PHARMA CONSULT is Vincent BILLE.
Directors
According to the 2025 annual accounts
Vincent BILLE
Director
Establishments
Establishment units
Physical locations of this company
Rue du Village 51A
1380 Lasne
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
OVH Mail
Hosting
OVH, FR
DNS
OVH DNS
Domain
Domain
marblepharmaconsult.com
Registered
2007-04-21
Registrar
OVH, SAS
Expires
2026-04-21
Website info
Features
Security
Details
- Company number
- 0889.606.695
- VAT number
- BE 0889.606.695
- Registered office
- Rue du Village 51A, 1380 Lasne
- Names & denominations
- MARBLE PHARMA CONSULT
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 23 May 2007
- Peppol
- Active · Active since 23 Nov 2025
- Contact
- marblepharmaconsult.com
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overig speur- en ontwikkelingswerk op natuurwetenschappelijk gebied
Overige zakelijke dienstverlening, neg
Overige adviesbureaus op het gebied van bedrijfsvoering en beheer
Overige zakelijke dienstverlening, n.e.g.
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering